AI Engines For more Details: Perplexity Kagi Labs You
Motion Sickness: Scopolamine-N-oxide hydrobromide is commonly used to prevent motion sickness and associated symptoms such as nausea, vomiting, and dizziness. It works by blocking the action of acetylcholine in the vestibular system, reducing the signals that cause motion sickness.
Nausea and Vomiting: In addition to motion sickness, scopolamine-N-oxide hydrobromide may be used to alleviate nausea and vomiting associated with other conditions, such as postoperative nausea and vomiting (PONV) or chemotherapy-induced nausea and vomiting (CINV).
Preoperative Medication: Scopolamine-N-oxide hydrobromide may be administered before surgery to reduce salivation and respiratory secretions, as well as to prevent nausea and vomiting during and after surgery.
Anesthesia: Scopolamine-N-oxide hydrobromide can be used as an adjunct to anesthesia to help induce relaxation, reduce salivation, and prevent laryngospasm during intubation.
Anticholinergic Effects: As an anticholinergic medication, scopolamine-N-oxide hydrobromide blocks the action of acetylcholine in the central and peripheral nervous systems. This can lead to various effects such as decreased gastrointestinal motility, decreased bronchial secretions, pupil dilation (mydriasis), and decreased sweating (anhidrosis).
Ophthalmic Applications: Scopolamine-N-oxide hydrobromide may be used in ophthalmology to induce mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation) for diagnostic or therapeutic purposes.
Transdermal Patch: In some formulations, scopolamine-N-oxide hydrobromide is available as a transdermal patch for the prevention of motion sickness. The patch delivers a controlled dose of the medication through the skin over a period of several days.
Side Effects: Common side effects of scopolamine-N-oxide hydrobromide may include dry mouth, blurred vision, constipation, urinary retention, drowsiness, confusion, and dizziness. These side effects are typically dose-dependent and may vary among individuals.
Contraindications: Scopolamine-N-oxide hydrobromide is contraindicated in individuals with glaucoma, severe hepatic or renal impairment, urinary retention, paralytic ileus, or hypersensitivity to anticholinergic medications.
Drug Interactions: Scopolamine-N-oxide hydrobromide may interact with other medications, particularly other anticholinergic drugs, leading to enhanced anticholinergic effects. Patients should inform their healthcare providers about all medications, supplements, and herbal products they are taking before using scopolamine-N-oxide hydrobromide.
Rank | Probiotic | Impact |
---|---|---|
species | Lacticaseibacillus paracasei | Reduces |
species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
1 | 0 | Parabacteroides distasonis | species | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0 | 0 | |
Age-Related Macular Degeneration and Glaucoma | 0 | 0 | |
Allergic Rhinitis (Hay Fever) | 0 | 0 | |
Allergies | 0 | 0 | |
Allergy to milk products | 0 | 0 | |
Alopecia (Hair Loss) | 0.1 | 0.1 | |
Alzheimer's disease | 0 | 0 | |
Ankylosing spondylitis | 0.1 | 0.1 | |
Anorexia Nervosa | 0 | 0 | |
Atrial fibrillation | 0 | 0 | 0 |
Autism | 0 | 0.1 | 0 |
Bipolar Disorder | 0 | 0 | |
Cancer (General) | 0.3 | -0.3 | |
Carcinoma | 0 | 0 | 0 |
Celiac Disease | 0 | 0 | |
Chronic Fatigue Syndrome | 0.2 | 0.1 | 1 |
Chronic Kidney Disease | 0 | 0 | |
Coagulation / Micro clot triggering bacteria | 0 | 0 | |
Cognitive Function | 0 | 0 | |
Colorectal Cancer | 0 | 0 | |
COVID-19 | 0 | 0 | |
Crohn's Disease | 0.1 | 0 | 0 |
Depression | 0.4 | 0.3 | 0.33 |
Endometriosis | 0 | 0 | |
Epilepsy | 0 | 0 | |
Fibromyalgia | 0 | 0 | |
Functional constipation / chronic idiopathic constipation | 0 | 0 | 0 |
gallstone disease (gsd) | 0 | 0 | |
Graves' disease | 0 | 0 | |
Heart Failure | 0 | 0 | |
hemorrhagic stroke | 0 | 0 | |
hyperglycemia | 0 | 0 | |
hypertension (High Blood Pressure | 0 | 0 | |
Hypoxia | 0 | 0 | |
IgA nephropathy (IgAN) | 0 | 0 | |
Inflammatory Bowel Disease | 0 | 0.1 | 0 |
Intracranial aneurysms | 0 | 0 | |
Irritable Bowel Syndrome | 0 | 0 | |
ischemic stroke | 0 | 0 | |
Liver Cirrhosis | 0 | 0 | |
Long COVID | 0 | 0 | 0 |
ME/CFS without IBS | 0.1 | -0.1 | |
Metabolic Syndrome | 0 | 0 | 0 |
Mood Disorders | 0.4 | 0.3 | 0.33 |
Multiple Sclerosis | 0 | 0.1 | 0 |
neuropathic pain | 0 | 0 | |
Neuropathy (all types) | 0 | 0 | |
Obesity | 0 | 0.3 | 0 |
obsessive-compulsive disorder | 0 | 0 | |
Parkinson's Disease | 0 | 0 | |
Polycystic ovary syndrome | 0.1 | 0.1 | |
Premenstrual dysphoric disorder | 0 | 0 | |
Primary sclerosing cholangitis | 0 | 0.1 | 0 |
Psoriasis | 0.1 | -0.1 | |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0 | 0 | |
Schizophrenia | 0 | 0 | 0 |
Sjögren syndrome | 0 | 0 | 0 |
Stress / posttraumatic stress disorder | 0 | 0 | 0 |
Systemic Lupus Erythematosus | 0 | 0 | |
Type 2 Diabetes | 0 | 0.2 | 0 |
Ulcerative colitis | 0.2 | 0 | 0 |
Unhealthy Ageing | 0 | 0 | |
Vitiligo | 0 | 0 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]